An overview of patient monitoring strategies experts use to establish individualized followup with patients receiving therapy for OAB in the third-line setting.
Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.
Sponsored by AbbVie US Medical Affairs
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
cUTI Roundtable: Discussing and diagnosing these difficult infections
July 10th 2024This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.
Read More